I agree. This is a setback for now but the company will emerge stronger as all the questions about the platform are put to rest. This story was never entirely about one drug for Gaucher's disease. That would have been nice but on approval we will get some of that market based on pricing alone.
I am long and have been tempted to play the game of getting out and trying to get back in at a lower price. That is so difficult to do. I believe in the company and will hold my shares and add on weakness as appropriate. Nothing has really changed except that the FDA wants more info which means they are taking this NDA very seriously and understands that the approval of this drug has much larger implications for the future of protein synthesis.